Pharmacotherapy for the prevention of post-ERCP pancreatitis

Erina Foster, Joseph Leung

Research output: Contribution to journalArticlepeer-review

15 Scopus citations


Post-ERCP pancreatitis (PEP) is a potential complication of ERCP. Pharmacotherapy for prevention of PEP aims at reducing basal sphincter pressure and contractility or a decrease in pancreatic secretion to reduce intraductal pressure. Timing and route of administration of drugs are critical to ensure maximum benefits from medications. Pancreatic stenting offers an alternative to decompress the pancreas and is effective in reducing PEP in high-risk patients.

Original languageEnglish (US)
Pages (from-to)52-55
Number of pages4
JournalAmerican Journal of Gastroenterology
Issue number1
StatePublished - Jan 2007

ASJC Scopus subject areas

  • Gastroenterology


Dive into the research topics of 'Pharmacotherapy for the prevention of post-ERCP pancreatitis'. Together they form a unique fingerprint.

Cite this